Multi-target anti-angiogenic small molecule
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Multi-target anti-angiogenic small molecule, covering 2026-02-06 to 2026-02-06. Get the full timeline:
Most recent: Clinical Trial Update: Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients [Phase 2]